Clinical Trial

UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases

Withdrawn Early Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
Internal decision.
Summary
This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells（QT-019C） in With Relapse/Refractory Autoimmune Diseases.
Protocol Amendment History 3 changes
critical Trial status changed: Not Yet Recruiting → Withdrawn 2026-05-29
critical Reason stopped changed: — → Internal decision. 2026-05-29
notable Enrollment reduced: 15 -> 0 participants 2026-05-29
Trial Details
NCT Number NCT07410377
Lead Sponsor The Affiliated Hospital of Xuzhou Medical University
Collaborators: Shanghai Xiniao Biotech Co., Ltd.
Conditions Systemic Lupus Erythematosus, Inflammatory Myopathy
Start Date 2026-03
Primary Completion 2027-03 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-28